Clinical rationale of mood stabilizers in treating depression: Insights from prescriptions and adherence patterns

Hideyo Sugahara[a,*] and Shoji Tokunaga[b]

[a]Sugahara Tenjin Clinic, GG Solar Building, Tenjin 3-4-9 Chuo-ku, Fukuoka-city, Fukuoka 810-0001, Japan

[b]Medical Information Center, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

***Corresponding Author**: Hideyo Sugahara
Sugahara Tenjin Clinic
GG Solar Building, Tenjin 3-4-9 Chuo-ku, Fukuoka-city, Fukuoka 810-0001, Japan
Phone: +81-92-718-0720
Fax: +81-92-718-0721
Email: research01@mist.ocn.ne.jp

Author contributions

H.S. designed and developed the study, evaluated data quality, analyzed and interpreted the data, drafted and critically evaluated the manuscript. S.T. critically evaluated the manuscript and provided advice from a statistical perspective.

Acknowledgements: The authors are grateful to Akane Yoshida, Haruka Taniguchi, Honoka Matsunobu, Chie Koga, Fumine Matsubara, and Mei Shirouzu for their contributions to data acquisition and methodological discussions related to this research.

Data Availability Statement: All relevant data are provided within the manuscript and its tables and figures.

Funding Statement: The study was implemented in clinical practice and was not supported by any grants or funding.

Conflict of Interest Disclosure: The author has no conflicts of interest to disclose.

Ethics Approval Statement: This study was approved by the Ethics Committee of Tohoku University (approval no: 2024-1-136; approval date: May 29, 2024).

Patient Consent Statement: Informed consent was obtained from patients in an optout manner between May and August 2024.

Abstract

Background

Mood stabilizers, such as lithium and valproate, are infrequently prescribed for unipolar depression despite their proven efficacy in reducing depression-related suicide rates as well as managing migraines. Recognizing their potential benefits, this study aimed to investigate the effects of increased mood stabilizer prescriptions on depression, particularly following initial consultation, and compare these effects among patients with unipolar and bipolar depression variants.

Methods

This retrospective cohort study analyzed data from 300 patients with a diagnosis of depression in 2016, 2019, and 2022 (100 patients per year). Medical records were reviewed to evaluate the regularity of hospital visits and the continuous use of mood stabilizers and antidepressants over 6 months. Patient adherence to hospital visits was used as a treatment success metric. Kaplan–Meier survival analysis and Cox proportional hazards models were applied to evaluate the impact of medication regimens on patient retention during this period.

Results

The prescription rate for mood stabilizers gradually increased from 27% in 2016 to 89% in 2022, primarily driven by lithium prescriptions. Kaplan–Meier and Cox proportional hazards analyses demonstrated improved patient retention regarding hospital visits over 6 months, with mood stabilizers significantly reducing treatment discontinuation in patients with unipolar depression (n=184) over 3 years (hazard ratio: 0.44; 95% confidence interval: 0.24–0.83; p=0.01).

Conclusion

Mood stabilizers, particularly lithium, are effective in patients with unipolar depression as well as in those with bipolar mood disorders. Incorporating mood stabilizers into standard care strategies for unipolar depression warrants further exploration.

Keywords: mood stabilizer, unipolar depression, lithium, valproic acid, treatment adherence

1 INTRODUCTION

People with bipolar disorder are typically prescribed mood stabilizers or antipsychotics,[1,2] whereas those with unipolar depression frequently receive treatment with antidepressants.[1,3,4] A substantial proportion of outpatients with either condition continue to experience suicidal ideation, despite treatment.[5] Geological analyses of drinking water demonstrated that lithium, a mood-stabilizing agent, is the only psychiatric medication empirically proven to reduce suicide completion rates.[6,7] Furthermore, meta-analyses consistently indicate a reduction in suicidal behavior and mortality during long-term treatment with lithium salts, benefiting patients with bipolar disorder and possibly those with unipolar, recurrent major depression.[8,9] Additionally, valproic acid can prevent migraines associated with depression.[10] Therefore, mood stabilizers hold promise not only in managing bipolar disorder but also in mitigating the suicide risk and addressing migraine symptoms in unipolar depression.[11-14]

These medications may be effective as standalone treatments for unipolar depression, rather than being limited to the augmentation of antidepressants in treatment-resistant depression, manic symptoms in bipolar disorder, prophylactic use for relapse,[1,15] and suicidal tendencies and migraines.[8-14] This hypothesis was derived from the author's daily clinical practice. Since 2005, the main author has transitioned from academia to practicing clinical psychiatry at a private clinic in Fukuoka, a metropolitan city in Japan. Over the past 19 years, the author has treated more than 5,000 patients with mood disorders, adhering to the principle of "providing the optimal treatment for each patient at that specific point in time." Based on the author’s clinical experiences and observations, as well as the increasing frequency of mood stabilizer prescriptions observed in recent years, this study aimed to assess the efficacy of mood stabilizers in the treatment of depression, encompassing both unipolar and bipolar variants.

2 MATERIALS AND METHODS

This retrospective cohort study was inspired by recent increases in mood stabilizer prescriptions to evaluate the impact of mood stabilizers on depression. The medical records of 300 patients with mood disorders (100 patients per year) in 2016, 2019, and 2022 were reviewed, and patient demographics, prescribed mood stabilizers and antidepressants, and the frequency of hospital visits during the initial 6 months of treatment were assessed.

Hospital visits (medication adherence) were used as a proxy for drug efficacy, given their critical

role in psychiatric treatment outcomes, particularly for chronic mood disorders.[16] The sample size was calculated to achieve 80% power at a two-sided significance level of 5%, assuming a 6-month continuation rate of 30% in 2016 and 55% in 2022, resulting in a required minimum of 87 cases. This study was approved by the Ethics Committee of Tohoku University and adhered to the Strengthening the Reporting of Observational studies in Epidemiology statement.

2.1 Participants

This study included 100 consecutive patients (each year) who met the inclusion criteria and initiated clinic visits on or after April 1. Patients with charts from April 1 of each year that showed unipolar or bipolar depressive illnesses and who were considered to have started ongoing drug treatment at our clinic were included. In addition to visits for non-treatment purposes such as family consultations and second opinions, patients receiving treatment in internal medicine, patients with psychiatric disorders other than depression, patients who did not require regular drug treatment such as mild depression, simple anxiety, or mild sleep disorders, patients seeking only a diagnosis or transfer, and patients refusing continuous drug treatment were excluded (Figure 1). The study timing was chosen to minimize potential seasonal variations in disease presentation and patient characteristics.

At their initial visit, patients completed a comprehensive questionnaire of approximately 100 questions, including the Center for Epidemiologic Studies Depression Scale (CES-D; the self-rating depression scale),[17] followed by a 30-min interview with a nurse and a 40–60-min physician consultation. Treatment protocols adhered to standard guidelines, which recommend medication continuation for at least 6–9 months after symptom improvement in cases of single depressive episodes and even longer for recurrent cases.[1] Disorders were assigned based on Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria, with unipolar major depressive disorder (MDD) distinguished from bipolar disorder.[18] For the diagnosis of bipolar disorder, hypomanic or manic episodes were not strictly required, as the assessment also considered cyclothymic and hyperthymic temperaments, alongside life and family history, based on the bipolar spectrum model.[19-21] In cases where bipolarity was confirmed, unipolar depression diagnoses were excluded. In 2016, mood stabilizers were primarily prescribed to patients with bipolar disorder, while lithium and valproic acid were being investigated for suicide prevention and migraine treatment, respectively. However, prescriptions evolved and mood stabilizers were increasingly prescribed over time, when deemed appropriate by the author's clinical judgment rather than exclusively for bipolar disorder, suicidal ideation, or migraine. For unipolar depression, mood stabilizers were frequently utilized when mood fluctuations were suspected, such as in atypical depression[22] or exhausted depression attributed to hypomanic hyperactivity.[20,23] Persistent mild depression, such as neurotic depression,

generally did not warrant mood stabilizer use.

Patients were informed that lithium was “approved in Japan for the treatment of mania and manic episodes”[24] and that valproic acid was “approved for the treatment of mania, manic episodes, epilepsy, and migraine prevention.”[25] Additionally, they were informed that if these approved indications were not applicable, the medication would be prescribed on an off-label basis. Informed consent was obtained from all patients prior to treatment initiation. Verbal checks were regularly conducted to address treatment-related inquiries or concerns during follow-up visits. Information regarding suicidal ideation was obtained from a health questionnaire completed prior to the consultation, specifically from binary (yes/no) responses to questions about suicidal thoughts. Patients with persistent suicidal ideation or concerns about agitation and impulsive behaviors were treated with risperidone or other antipsychotics,[26] with clear instructions for as-needed use. Anxiolytics (e.g., lorazepam) were prescribed solely for acute symptom relief, whereas hypnotic agents (e.g., eszopiclone, brotizolam) were prescribed on an as-needed basis.

2.2 Data Analyses

Descriptive statistics for the study variables were calculated and presented as means with standard deviations. It was presumed that all patients were prescribed mood stabilizers and antidepressants, including prescriptions for single-use cases. The mean maximum dose administered during the study period was calculated to determine the highest average dose. The average medication duration was calculated from the total periods of administration within 6 months. The 6-month retention rate of participants was analyzed annually using the Kaplan–Meier method, with curves generated to account for age, sex, illness (unipolar or bipolar), presence of suicidal ideation, and CES-D score. Differences between years were examined using Cox regression analysis, adjusting for these five factors. In 2022, three patients did not respond to the suicidal ideation questionnaire, reducing the total sample to 297 for this aspect of the analysis. When evaluating the effects of antidepressants and mood stabilizers based on treatment adherence, the length of hospital visits from the initial consultation cannot accurately serve as an indicator of the effects of medications introduced after the initial visit. The analysis excluded 11 patients with bipolar disorder and 19 patients with unipolar depression who were receiving both antidepressants and mood stabilizers for this reason. As a result, the analysis included 85 patients with bipolar disorder and 185 patients with unipolar depression who were evaluated for treatment continuity. The survival curves of patients with unipolar depression (n=184; 1 patient had missing response for suicidal ideation question) were analyzed and compared across those taking antidepressants, mood stabilizers, or a combination of both to assess the impact of these medications on the frequency of ongoing hospital visits.

Factors influencing 6-month retention rates and reasons for discontinuation before this time point were examined. Two nurses independently reviewed medical records and associated documentation to identify these factors using predetermined criteria based on patients' subjective reports documented in their medical records. Statements such as "improving," "feeling better," or "not getting better" were extracted as reasons for continued or interrupted visits. Discrepancies in assessments were resolved through consensus discussions. The aggregated findings were then categorized and ranked by frequency within each category.

Analysis of variance was used to detect variations in means across variables, whereas the Kaplan–Meier method and Cox regression analysis were used to identify differences in hospital attendance rates. All statistical analyses were conducted using EZR,[27] with the significance level set at $p<0.05$.

3 RESULTS

In the years 2016, 2019, and 2022, certain cases were excluded from the medical record survey due to clinical limitations, including family consultations and second opinions and similar circumstances (3, 3, and 1 patient per year, respectively), treatments for internal medicine conditions (47, 24, and 0 patients per year), and other psychiatric conditions not necessitating regular treatment (31, 25, and 13 patients per year). Exclusions due to a lack of intention to undergo treatment were recorded as 9, 1, 11, and 0 (2016), 5, 2, 6, and 1 (2019), and 9, 6, 2, and 2 (2022) for visits related to obtaining a medical certificate, refusing treatment, declining medication, and earlier transfers, respectively. In the corresponding years, 21, 14, and 19 patients opted out of treatment, resulting in the exclusion of 102 individuals in 2016, 66 in 2019, and 33 in 2022 (Table 1, Figure 1). The consultation dates for the 100th participant post-April 1 were October 19, 2016; September 9, 2019; and August 10, 2022.

Table 1 shows the demographic characteristics, indicating a steady decline in the mean age from 36.6 years in 2016 to 30.1 years in 2022, reflecting a 6.5-year decrease. The sex ratio tended to favor women, particularly in 2019 (ratio: 2.3). Initial consultations revealed that, on average, 68.0% of patients had unipolar depression and 32.0% had bipolar disorder annually. In 2022, over 65% of patients reported suicidal ideation, compared to an overall average of 45.8% across the study period.

Prescription trends over 6 months indicated an increase in lithium prescriptions every 3 years, whereas valproic acid prescriptions exhibited an increase during the initial three-year period;

however, no consistent trend was observed subsequently. The prevalence of total mood stabilizer prescriptions increased progressively from 27% in 2016 to 56% in 2019 and 89% in 2022 (Table 2). Conversely, antidepressant prescriptions decreased from 86% in 2016 to 62% in 2022, with sulpiride constituting more than half of these prescriptions. Sertraline, escitalopram, and mirtazapine were also commonly prescribed, although their use varied annually, whereas other antidepressants were less commonly prescribed. The rate of patients prescribed only mood stabilizers increased from 14% in 2016 to 38% in 2022 (Table 2). Initially, most patients experienced annual depressive episodes occasionally with mood instability but no pronounced manic symptoms.

Kaplan–Meier survival analysis of 6-month hospital attendance rates over 3 years (Figure 2), adjusted for age, sex, illness, CES-D score, and presence of suicidal ideation (n=297), showed an increase over time. Cox proportional hazards analysis, adjusting for the same variables, indicated a significant year effect on hospital visits (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.67–0.98; p=0.03), suggesting increased attendance over time. For all participants (n=270), univariate Cox proportional hazards analysis showed a significant association between mood stabilizer prescriptions and hospital visits (HR: 0.69; 95% CI: 0.51–0.93; p=0.02), whereas antidepressants had a nonsignificant effect (HR: 0.95; 95% CI: 0.68–1.33; p=0.75). Bivariate analysis revealed an HR of 0.53 (95% CI: 0.35–0.79; p=0.002) for mood stabilizers and 0.62 (95% CI: 0.39–0.97; p=0.04) for antidepressants. The data also revealed a significant association between mood stabilizer prescriptions and hospital visits in patients with unipolar depression.

A subgroup analysis of 185 patients with unipolar depression revealed distinct continuation rates. Univariate Cox models showed significant associations for mood stabilizers (HR: 0.66; 95% CI: 0.45–0.98; p=0.04) but not for antidepressants (HR: 0.98; 95% CI: 0.58–1.66; p=0.93). Similarly, bivariate models showed significant results for mood stabilizers (HR: 0.56, 95% CI: 0.35–0.90; p=0.02) but not for antidepressants (HR: 0.63; 95% CI: 0.33–1.21; p=0.17). When adjusted for age, sex, CES-D score, presence of suicidal ideation, and year (n=184), a significant difference in continuation rates was observed among patients taking mood stabilizers, antidepressants, or both (Figure 3). A statistically significant difference in the survival curves for continued hospital visits was consistently observed between the antidepressant alone group and the mood stabilizer co-administration group, from 2 to 20 weeks after the first visit. The mood stabilizer alone group had a higher rate of continued visits than the antidepressant alone group, but this was not significantly different from the other two groups. Cox proportional hazards analysis, which accounted for these five factors and use of mood stabilizers and antidepressants, revealed that antidepressant use demonstrated an HR of 0.57 (95% CI: 0.29–1.13; p=0.11), whereas mood stabilizer use demonstrated an HR of 0.44 (95% CI: 0.24–0.83; p=0.01), indicating significantly higher retention

rates for patients with unipolar depression who were prescribed mood stabilizers.

Medical records detailed the reasons for continued or discontinued hospital visits. In 2016 and 2022, the primary reason for continued visits 6 months post-initial consultation was “effective treatment or patient improvement,” whereas in 2019, it was “insufficient improvement necessitating continued hospital visits.” Reasons for discontinuation within 6 months included “fatigue from hospital visits,” “inconvenient waiting times or environment,” “adequate recovery,” and “employment obligations or reluctance to take additional leave.”

4 DISCUSSION

This study’s results suggest that mood stabilizers may be effective not only for bipolar depression but also for unipolar depression, despite the limited supporting evidence.[28-30] In our medical facility, there has been a notable increase in the number of mood stabilizer prescriptions for depression and higher treatment retention rates within the first 6 months. The prescription rates for mood stabilizers rose progressively from 27% in 2016 to 56% in 2019 and 89% in 2022 (Table 2). The 6-month retention rates demonstrated a triennial increase starting in 2016 (Figure 2). Patients with unipolar depression who were treated with mood stabilizers exhibited consistently higher retention rates (Figure 3). In this subgroup (n=184), mood stabilizers had a statistically significant HR of 0.44 after adjusting for relevant factors. The participants were new patients who met specific criteria, including a diagnosis of depression and initiation of medication within a certain timeframe. The follow-up visit rate was used as an indirect indicator of treatment efficacy. The results suggest that mood stabilizers, notably lithium, were beneficial for all patients with depression, including those with unipolar depression. The efficacy of mood stabilizers from the initial phases of treatment corroborated clinical assessments.

The diagnostic distribution of mood disorders at initial clinical encounters demonstrated a 2:1 ratio, with 68.0% classified as unipolar depression and 32.0% as bipolar depression, exhibiting annual variation. In contrast, the DSM-IV 12-month prevalence rates in the United States indicate a 5:1 ratio for MDD (7%) versus bipolar I and II disorders combined (1.4%; 0.6% and 0.8%, respectively).[18]

Over 45% (45.8%) of the study participants reported suicidal ideation at the initial consultation, with projections exceeding 65% by 2022. Misdiagnosing bipolar disorder as unipolar depression and prescribing antidepressants in such cases may increase the risk of suicide due to medication-induced

mania or activation syndromes. Consequently, mood stabilizers are critical in suspected cases of bipolar disorder to mitigate adverse outcomes.[19,31,32]

Geological studies have suggested an association between trace lithium levels in drinking water and reduced suicide rates in local populations.[6,7] Some reviews on randomized controlled trials comparing lithium with placebos or alternative treatments have updated the evidence for lithium's role in reducing suicidal behavior and have proposed that higher levels of lithium in drinking water may be associated with lower suicide rates.[8,9] A German study analyzing data from nearly 100,000 inpatients in Bavaria between 2014 and 2021 found a consistent 4.6% rate of lithium use for unipolar depression,[33] aligning with the 6.4% rate observed in our clinic in 2016. Although lithium use has declined globally,[34] particularly in Europe and the USA, it has shown a slight increase in Asian countries.[35]

Lithium has long been recognized as a potential treatment for treatment-resistant depression, in addition to its established role in managing mania.[36] However, mood stabilizers, including lithium, are rarely considered viable options for treating unipolar depression.[29,30.37] This underutilization persists despite evidence suggesting substantial benefits of lithium for severe MDD. [29,30.38,39] Several factors contribute to the phenomenon. One issue stems from the dichotomic classification of mood disorders into unipolar depression and bipolar disorder by the DSM-III in 1980.[40] Bipolar disorders require a confirmed hypomanic or manic episode for diagnosis, with depressive episodes typically outnumbering and outlasting manic episodes.[41] Because hypomanic or manic phases are often underrecognized by patients, bipolar disorder is frequently misdiagnosed as unipolar depression during initial depressive episodes. The development of novel antidepressants also plays a significant role. The pharmaceutical industry may have profit-driven motivations to expeditiously introduce innovative antidepressants that address societal needs.[42,43] Over the past four decades, quite a few new antidepressants, such as serotonin reuptake inhibitors (SRIs) and serotonin noradrenaline reuptake inhibitors, which have reduced side effects for unipolar depression, have emerged. However, the evaluation of these drugs has typically been limited to 6-week clinical trials conducted on patients with low suicide risk. Despite showing only slight improvements over a placebo, these drugs have received widespread regulatory approval. Since the introduction of fluoxetine, the first second-generation SRI antidepressant, in the United States in 1987, approximately 20 new antidepressants have been developed worldwide. In contrast, only one mood stabilizer, lamotrigine, was developed during this period. Concurrently, treatment-resistant depression has emerged as a significant issue, with numerous patients failing to respond to antidepressant therapy.[44,45] This has led to the approval of expensive new antipsychotic medications as adjunctive treatments for major depressive disorders unresponsive to standard antidepressants.[46] For lithium, the limited insurance

coverage, often restricted to mania and manic states in many countries like Japan, coupled with a lack of understanding of side effects, may be overemphasizing the harmful effects of lithium. In this study, the observed side effects of lithium were minimal, consisting primarily of occasional gastrointestinal symptoms, such as diarrhea, or finger tremor. These were effectively managed through dosage adjustments or discontinuation. Lithium dosages were standardized to minimize the risk of renal impairment with long-term use, with maximum daily doses ranging from 200 to 500 mg. For valproate, side effects were limited to somnolence or feelings of listlessness (valproate administration to people of reproductive potential was avoided owing to teratogenic effects), with dosages maintained at 200–400 mg per day (Table 2). Notably, the low starting dose of lithium, the smallest dose being 100 mg, likely contributed to the high rates of treatment continuation observed.

Concerning the reason for visiting hospital, patients who continued treatment 6 months after their initial consultation were frequently classified as experiencing “improvement” or “insufficient improvement,” suggesting that their continued hospital visits were motivated by a positive expectation of recovery. Consequently, the follow-up visit frequency may serve as an indirect indicator of treatment efficacy.[16] The administration of mood stabilizers, such as lithium, to individuals with mood disorders appeared highly beneficial in improving their conditions and maintaining their optimism for recovery.

The study period coincided with significant societal challenges, including the onset of the COVID-19 pandemic in 2020 and the conflict in Ukraine in 2022. During the pandemic, Japan experienced a notable increase in suicides among women.[47] Additionally, in 2022, internal medicine outpatient services at the hospital were discontinued due to the institutional limitations regarding patients with fever. These diverse social contexts must be considered when analyzing the study's results, as societal conditions are continuously evolving, rendering year-to-year comparisons complex. However, the clinic maintained a consistent operational environment during the study period, with stable consultation schedules, no closures exceeding continuous 10 days, and no utilization of substitute physicians over the past decade.

Taken together, the early availability of adjunctive or simple low-dose mood stabilizers, such as lithium and valproate, may offer superior efficacy and ethical advantages, compared with antidepressants alone. Therefore, standard treatment guidelines for unipolar depression may need revision to include mood stabilizers more proactively, pending confirmation from larger studies like randomized controlled trials comparing mood stabilizers, combination therapy with antidepressants, and antidepressants alone. Barriers to the broader use of mood stabilizers may include clinicians’ reliance on traditional prescribing practices and the influence of pharmaceutical companies

promoting newer antidepressant medications.

4.1 Strengths and limitations

Leveraging the recent increase in mood stabilizer prescriptions for patients with depression at our clinic, we conducted a retrospective cohort study to evaluate their treatment efficacy. The results demonstrated significant benefits of mood stabilizers even in unipolar depression. These real-world outcomes strengthened the study's findings. However, the study had limitations, including its restriction to a single physician and clinic, a small sample size, and the potential for prescription bias (especially in the selection of antidepressants). Despite these limitations, the consistent treatment approach reflects the physician's adherence to optimal patient care based on three decades of clinical experience. Using hospital visit frequency as a proxy for treatment efficacy requires caution in interpretations, as it is an indirect measure. However, patients who discontinue treatment early often experience poor outcomes. Conversely, consistent follow-up appointments indicate patient engagement, which is crucial to effective treatment. Therefore, treatment continuation rates are theoretically and empirically associated with treatment success.

5 CONCLUSIONS

This study demonstrates that mood stabilizers, particularly lithium and valproate at low doses, effectively improve treatment outcomes in unipolar depression, as indicated by high treatment retention rates and manageable side effects. These findings highlight the underrecognized potential of mood stabilizers in managing unipolar depression, warranting further research to validate their efficacy and optimize their application across diverse clinical settings.

References

1. Taylor DM, Barnes TRE, Young AH. *The Maudsley Prescribing Guidelines in Psychiatry.* 13th ed. WILEY Blackwell; 2019.

2. Yatham LN, Chakrabarty T, Bond DJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. *Bipolar Disord.* 2021;23(8):767-788. doi:10.1111/bdi.13135

3. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. *Am J*

Psychiatry. 2006;163(7):1161-1172. doi:10.1176/ajp.2006.163.7.1161

4. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. *Can J Psychiatry*. 2016;61(9):540-560. doi:10.1177/0706743716659417

5. Gao K, Wu R, Wang Z, et al. Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder. *J Psychiatr Res*. 2015;60:117-124. doi:10.1016/j.jpsychires.2014.09.011

6. Schrauzer GN, Shrestha KP. Lithium in drinking water and the incidences of crimes, suicides, and arrests related to drug addictions. *Biol Trace Elem Res*. 1990;25(2):105-113. doi:10.1007/BF02990271

7. Eyre-Watt B, Mahendran E, Suetani S, et al. The association between lithium in drinking water and neuropsychiatric outcomes: a systematic review and meta-analysis of 2678 regions containing 113 million people. *Aust N Z J Psychiatry*. 2021;55(2):139-152. doi:10.1177/0004867420963740

8. Cipriani A, Hawton H, Stockton S, Geddes JR, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ*. 2013;346:f3646. doi:10.1136/bmj.f3646

9. Tondo L, Baldessarini RJ. Prevention of suicidal behavior with lithium treatment in patients with recurrent mood disorders. *Int J Bipolar Disord*. 2024;12(1):6. doi:10.1136/bmj.f3646

10. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid, sodium valproate, or a combination of the two) for the prophylaxis of episodic migraine in adults. *Cochrane Database Syst Rev*. 2013;2013(6):CD010611. doi:10.1002/14651858.CD010611

11. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. *Am J Psychiatry*. 2005;162:1805-1819. doi:10.1176/appi.ajp.162.10.1805

12. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. *J Clin Psychiatry*. 2007;68(3):380-383. doi:10.4088/jcp.v68n0304

13. Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. *Harv Rev Psychiatry*. 2009;17(4):231-241. doi:10.1080/10673220903129814

14. Leo RJ, Singh J. Migraine headache and bipolar disorder comorbidity: a systematic review of the literature and clinical implications. *Scand J Pain*. 2016;11:136-145. doi:10.1016/j.sjpain.2015.12.002

15. Rybakowski JK, Ferensztajn-Rochowiak E. Updated perspectives on how and when lithium should be used in the treatment of mood disorders. *Expert Rev Neurother*. 2023;23(2):157-167.

doi:10.1080/14737175.2023.2181076

16. Patel MX, David AS. Medication adherence: predictive factors and enhancement strategies. *Psychiatry*. 2004;3(10):41-44. doi:10.1383/psyt.3.10.41.52405

17. Carpenter JS, Andrykowski MA, Wilson J, et al. Psychometrics for two short forms of the Center for Epidemiologic Studies-Depression Scale. *Issues Ment Health Nurs*. 1998;19(5):481-494. doi:10.1080/016128498248917

18. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. APA; 2013

19. Ghaemi SN, Ko JY, Goodwin FK. The bipolar spectrum and the antidepressant view of the world. *J Psychiatr Pract*. 2001;7(5);287-297. doi: 10.1097/00131746-200109000-00002

20. Benazzi F. Bipolar disorder—focus on bipolar II disorder and mixed depression. *Lancet*. 2007;369(9565):935-945. doi:10.1016/S0140-6736(07)60453-X

21. Amedei SG, Catena M, Lejeune F, Duma S, Scarpato MA, Faravelli C. Depression and bipolar disorder: is prevention of mania possible? Critical issues on diagnostic criteria. *Eur Psychiatry*. 2009;24(Suppl 1):S50-S01. dou:10.1016/S0924-9338(09)70482-1

22. Mallmann MB, Lopes FL, Veras AB. Chapter 7. Bipolar I Mania and Atypical Depression. In: *Psychotic Disorders*. Elsevier; 2021:93-106. doi:10.1016/b978-0-323-68309-8.00007-2

23. Smedler E, Sparding T, Landén M, Hattab A, Sellgren CM, Landén M. Reporting trigger factors for (hypo)manic episodes in bipolar disorder: association with personality and prognosis. *Acta Psychiatr Scand*. 2020;141(6):534-540. doi:10.1111/acps.13174

24. LIMAS tables 200. Kusuri-no-Shiori (Drug Information Sheet. Updated October 2022. Accessed December 3, 2024. https://www.rad-ar.or.jp/siori/english/search/result?n=45250

25. DEPAKENE-R Tables 100mg [medication for migraine]. Kusuri-no-Shiori (Drug Information Sheet. Updated July 2023. Accessed December 3, 2024. https://www.rad-ar.or.jp/siori/english/search/result?n=33335

26. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. *Psychopharmacology*. 2003;166(4):315-332. doi:10.1007/s00213-002-1322-9

27. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. *Bone Marrow Transplant*. 2013;48(3):452-458. doi:10.1038/bmt.2012.244

28. Shim I-H, Woo YS, Kim M-D, Bahk W-M. Antidepressants and mood stabilizers: novel research avenues and clinical insights for bipolar depression. *Int J Mol Sci*. 2017;18(11):2406. doi:10.3390/ijms18112406

29. Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. *Cochrane Database Syst Rev*. 2006;2006(4):CD003492. doi:10.1002/14651858.CD003492.pub2

30. Bschor T. Lithium in the treatment of major depressive disorder. *Drugs*. 2014;74(8):855-862.

doi:10.1007/s40265-014-0220-x

31. Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. *J Affect Disord*. 2005;84(2-3):117-125. doi:10.1016/S0165-0327(03)00194-0

32. Culpepper L. Misdiagnosis of bipolar depression in primary care practices. *J Clin Psychiatry*. 2014;75(3):e05. doi:10.4088/JCP.13019tx1c

33. Kriner P, Severus E, Korbmacher J, Mußmann L, Seemueller F. Lithium prescription trends in psychiatric inpatient care 2014 to 2021: data from a Bavarian drug surveillance project. *Int J Bipolar Disord*. 2023;11(1):40. doi:10.1186/s40345-023-00323-6

34. Greil W, de Bardeci M, Nievergelt N, et al. Twenty-three years of declining lithium use: analysis of a pharmacoepidemiological dataset from German-speaking countries. *Pharmacopsychiatry*. 2024;57(6):296-303. doi:10.1055/a-2374-2386

35. Shuy YK, Santharan S, Chew QH, Sim K. International trends in lithium use for pharmacotherapy and clinical correlates in bipolar disorder: a scoping review. *Brain Sci*. 2024;14(1):102. doi:0.3390/brainsci14010102

36. Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. *Int J Psychiatry Clin Pract*. 2017;21(1):13-23. doi:10.1080/13651501.2016.1248852

37. Rybakowski JK. Lithium – past, present, future. *Int J Psychiatry Clin Pract*. 2020;24(4):330-340. doi:10.1080/13651501.2020.1775855

38. Dunlop B, Aaron M. Response to treatment with placebo, medication or psychotherapy in severe non-psychotic major depressive disorder. *Curr Psychiatry Rev*. 2010;6(1):28-45. doi:10.2174/157340010790596526

39. Undurraga J, Sim K, Tondo L, et al. Lithium treatment for unipolar major depressive disorder: systematic review. *J Psychopharmacol*. 2019;33(2):167-176. doi:10.1177/0269881118822161

40. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 3rd ed. APA; 1980.

41. Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and treatment of bipolar disorder: a review. *JAMA*. 2023;330(14):1370-1380. doi:10.1001/jama.2023.18588

42. Moncrieff J. Are antidepressants overrated? A review of methodological problems in antidepressant trials. *J Nerv Ment Dis*. 2001;189(5):288-295. doi:10.1097/00005053-200105000-00003

43. Cosgrove L, Patterson EH, Bursztajn HJ. Industry influence on mental health research: depression as a case example. *Front Med (Lausanne)*. 2023;10:1320304. doi:10.3389/fmed.2023.1320304

44. Maina G, Adami M, Ascione G, et al. Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel. *Ann Gen Psychiatry*. 2023;22(1):48. doi:10.1186/s12991-023-00478-7

45. Kessing LV, Ziersen SC, Andersen FM, et al. Comparative responses to 17 different antidepressants in major depressive disorder: results from a 2-year long-term nation-wide population-based study emulating a randomized trial. *Acta Psychiatr Scand*. 2024;149(5):378-388. doi:10.1111/acps.13673

46. Kato M, Shiosakai M, Kuwahara K, et al. Adjunctive brexpiprazole 1□mg and 2□mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study. *Psychiatry Clin Neurosci*. 2024;78(2):113-122. doi:10.1111/pcn.13615

47. Kikuchi K, Anzai T, Takahashi K. The unusual increase in suicides among women in Japan during the COVID-19 pandemic: a time-series analysis until October 2021. *J Epidemiol*. 2023;33(1):45-51. doi:10.2188/jea.JE20220186

Figure legends

Figure 1. Flowchart of participant inclusion. Participants were included based on the order of their initial visit date. Exclusion criteria included patients with medical illness or psychiatric conditions other than depression, those without the intention for standard treatment at the clinic, and inappropriate cases such as family consultations. Other reasons for exclusion included insufficient medical records (2016) and a lack of full attendance at the clinic (2019).

Figure 2. Kaplan–Meier analysis comparing treatment attendance across 2016, 2019, and 2022. The analysis depicts 6-month retention rates among all participants for each year. Cox regression analysis was adjusted for age, sex, illness, Center for Epidemiologic Studies Depression Scale (CES-D) score, and the presence of suicidal ideation (SI). CI, confidence interval

Figure 3. Kaplan–Meier analysis of treatment adherence in the unipolar depression subgroup. The analysis compares treatment adherence among participants receiving mood stabilizers, antidepressants, or both. Cox regression analysis was adjusted for age, sex, Center for Epidemiologic Studies Depression Scale (CES-D) score, the presence of suicidal ideation (SI), and year. In the Cox regression model, mood stabilizer (MS) and antidepressant (AD) were represented as binary variables, with 0 indicating not prescribed and 1 indicating prescribed. For all participants diagnosed with unipolar depression (n=184), hazard ratios for MS and AD were calculated, adjusting for these five factors. CI, confidence interval

Table 1. Demographic Characteristics of the Participants

Year	2016	2019	2022
N	100	100	100
Mean age (years)	36.6 (13.5)	32.9 (13.1)	30.1 (10.0)
Age range (years)	15～75	13～75	14～59
Women/men	63/37	78/22	69/31
Major depressive disorder (n)	78	59	67
Bipolar disorder (n)	22	41	33
Suicidal ideation (n)	33	39	64（unknown: 3）
Mean CES-D* score	35.4 (10.3)	35.7 (11.9)	38.0 (9.7)
Excluded participants (n)			
Reasons for disqualification			
Second opinion	1	0	0
Family consultation	1	2	1
Insufficient medical record	1	0	0
Not a full attendance	0	1	0
Medical illness	47	24	0**
Other psychiatric illness	31	25	13
No intention for continuous treatment	21	14	19
Total	102	66	33

Parentheses show the standard deviation.

*CES-D: The Center for Epidemiologic Studies Depression Scale

**In 2022, the outpatient internal medicine department was closed due to the COVID-19 pandemic.

Table 2. Mood Stabilizer and Antidepressant Prescriptions

Year	2016	2019	2022
Mood Stabilizer			
Li only (n)	19	37	69
Mean maximun dose (mg)	315.8(130.2)	213.5(127.3)	250.7(124.4)
Mean dosing period (weeks)	15.6(11.0)	16.9(11.4)	16.2(11.5)
VAP only (n)	7	15	7
Mean maximun dose (mg)	328.6(170.4)	253.3(164.2)	171.4(125.4)
Mean dosing period (weeks)	22.9(9.7)	10.4(11.3)	13.2(10.6)
Li＋VAP (n)	0	3	13
Mean maximun dose (mg)	—	166.7／200	292.3(103.8)／176.9(72.5)
Mean dosing period (weeks)	—	11.3／10.2	19.6(11.0)／16.5(8.5)
Lamotrigine (n)	2*	1	0
Net participants with any prescription (n)	27	56	89
Antidepressant			
Sulpiride (n)	47	38	54
Sertraline (n)	21	12	5
Escitalopram (n)	10	6	3
Mirtazapine (n)	12	2	5
Others** (n)	31	13	3
Net participants with any prescription (n)	86	68	62

Parentheses show the standard deviation Li: lithium carbonate; VAP: sodium valproate

*Of the two participants prescribed lamotrigine in 2016, one was concurrently using lithium carbonate.

**Other antidepressants include paroxetine (9), mianserin (9), duloxetine (7), trazodone (7), amitriptyline (7), fluvoxamine (6), nortoriptyline (1), and maprotiline (1).


2016
2019
2022
n=202
n=166
n=133
Consecutive medical records from April 1st each year
Reasons for Exclusion
n=3
Family consultation (n=2)
Insufficient medical record (n=1)
n=3
Family consultation (n=2)
Not a full attendance (n=1)
n=1
Family consultation (n=1)
Inappropriate subject or insufficient medical record
n=199
n=163
n=132
n=47
n=24
n=0
Medical illness
n=152
n=139
n=132
n=31
n=25
n=13
Other psychiatric illness
n=121
n=114
n=119
n=21
n=14
n=19
No intention for treatment
n=100
n=100
n=100



Number at risk

2022	97	71	64	56	51	45
2019	100	67	59	52	49	48
2016	100	60	52	42	40	36



Number at risk

MS+AD	40	32	30	27	24	21
MS	24	14	13	11	11	9
AD	120	67	59	46	43	39